MCID: PLM033
MIFTS: 60

Pulmonary Embolism

Categories: Blood diseases, Cardiovascular diseases, Respiratory diseases

Aliases & Classifications for Pulmonary Embolism

MalaCards integrated aliases for Pulmonary Embolism:

Name: Pulmonary Embolism 12 29 55 43 44 15 63 17 72 33
Pulmonary Artery Embolism 12
Pulmonary Embolus 12
Pulmonary Emboli 15

Classifications:



External Ids:

Disease Ontology 12 DOID:9477
MeSH 44 D011655
NCIt 50 C50713
SNOMED-CT 68 59282003
UMLS 72 C0034065

Summaries for Pulmonary Embolism

MedlinePlus : 43 What is a pulmonary embolism (PE)? A pulmonary embolism (PE) is a sudden blockage in a lung artery. It usually happens when a when a blood clot breaks loose and travels through the bloodstream to the lungs. PE is a serious condition that can cause Permanent damage to the lungs Low oxygen levels in your blood Damage to other organs in your body from not getting enough oxygen PE can be life-threatening, especially if a clot is large, or if there are many clots. What causes a pulmonary embolism (PE)? The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung. Who is at risk for a pulmonary embolism (PE)? Anyone can get a pulmonary embolism (PE), but certain things can raise your risk of PE: Having surgery, especially joint replacement surgery Certain medical conditions, including Cancers Heart diseases Lung diseases A broken hip or leg bone or other trauma Hormone-based medicines, such as birth control pills or hormone replacement therapy Pregnancy and childbirth. The risk is highest for about six weeks after childbirth. Not moving for long periods, such as being on bed rest, having a cast, or taking a long plane flight Age. Your risk increases as you get older, especially after age 40. Family history and genetics. Certain genetic changes that can increase your risk of blood clots and PE. Obesity What are the symptoms of a pulmonary embolism (PE)? Half the people who have pulmonary embolism have no symptoms. If you do have symptoms, they can include shortness of breath, chest pain or coughing up blood. Symptoms of a blood clot include warmth, swelling, pain, tenderness and redness of the leg. How is a pulmonary embolism (PE) diagnosed? It can be difficult to diagnose PE. To make a diagnosis, your health care provider will Take your medical history, including asking about your symptoms and risk factors for PE Do a physical exam Run some tests, including various imaging tests and possibly some blood tests What are the treatments for a pulmonary embolism (PE)? If you have PE, you need medical treatment right away. The goal of treatment is to break up clots and help keep other clots from forming. Treatment options include medicines and procedures. Medicines Anticoagulants, or blood thinners, keep blood clots from getting larger and stop new clots from forming. You might get them as an injection, a pill, or through an I.V. (intravenous). They can cause bleeding, especially if you are taking other medicines that also thin your blood, such as aspirin. Thrombolytics are medicines to dissolve blood clots. You may get them if you have large clots that cause severe symptoms or other serious complications. Thrombolytics can cause sudden bleeding, so they are used if your PE is serious and may be life-threatening. Procedures Catheter-assisted thrombus removal uses a flexible tube to reach a blood clot in your lung. Your health care provider can insert a tool in the tube to break up the clot or to deliver medicine through the tube. Usually you will get medicine to put you to sleep for this procedure. A vena cava filter may be used in some people who cannot take blood thinners. Your health care provider inserts a filter inside a large vein called the vena cava. The filter catches blood clots before they travel to the lungs, which prevents pulmonary embolism. But the filter does not stop new blood clots from forming. Can pulmonary embolism (PE) be prevented? Preventing new blood clots can prevent PE. Prevention may include Continuing to take blood thinners. It's also important to get regular checkups with your provider, to make sure that the dosage of your medicines is working to prevent blood clots but not causing bleeding. Heart-healthy lifestyle changes, such as heart-healthy eating, exercise, and, if you smoke, quitting smoking Using compression stockings to prevent deep vein thrombosis (DVT) Moving your legs when sitting for long periods of time (such as on long trips) Moving around as soon as possible after surgery or being confined to a bed NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Pulmonary Embolism, also known as pulmonary artery embolism, is related to chronic thromboembolic pulmonary hypertension and respiratory failure, and has symptoms including hemoptysis, snoring and coughing. An important gene associated with Pulmonary Embolism is PLAT (Plasminogen Activator, Tissue Type), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Phenprocoumon and Teriparatide have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 An artery disease characterized by a blockage of the main artery of the lung or one of its branches by a substance that has travelled from elsewhere in the body, e.g. a blood clot.

PubMed Health : 63 About pulmonary embolism: Pulmonary embolism (PULL-mun-ary EM-bo-lizm), or PE, is a sudden blockage in a lung artery. The blockage usually is caused by a blood clot that travels to the lung from a vein in the leg. A clot that forms in one part of the body and travels in the bloodstream to another part of the body is called an embolus (EM-bo-lus). PE is a serious condition that can:

Wikipedia : 75 Pulmonary embolism (PE) is a blockage of an artery in the lungs by a substance that has moved from... more...

Related Diseases for Pulmonary Embolism

Diseases related to Pulmonary Embolism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1054)
# Related Disease Score Top Affiliating Genes
1 chronic thromboembolic pulmonary hypertension 33.5 NPPB F2 CRP
2 respiratory failure 32.7 F3 CRP ALB
3 essential thrombocythemia 32.4 VWF SERPINE1 F3 F2
4 cardiogenic shock 32.1 PLAT NPPB
5 protein s deficiency 32.0 SERPINC1 MTHFR F5 F3 F2 APOH
6 protein c deficiency 31.9 SERPINC1 MTHFR F9 F5 F2
7 cardiac arrest 31.6 TNNT2 NPPB ALB
8 pulmonary hypertension 31.6 VWF PLAT NPPB F3
9 antithrombin iii deficiency 31.5 SERPINC1 MTHFR F5 F2 F10 APOH
10 pulmonary edema 31.3 NPPB F2 CRP
11 inferior myocardial infarction 31.2 PLAT NPPB
12 heparin-induced thrombocytopenia 31.1 SERPINC1 F3 F10
13 may-thurner syndrome 30.8 F5 APOH
14 atrial standstill 1 30.8 TNNT2 TNNI3 NPPB
15 post-thrombotic syndrome 30.8 SERPINE1 SERPINC1 F5 F2
16 acute cor pulmonale 30.8 SERPINF2 SERPINE1 PLAT NPPB
17 patent foramen ovale 30.7 SERPINC1 PLAT MTHFR F5 F2 APOH
18 esophageal varix 30.6 SERPINC1 F2 ALB
19 sticky platelet syndrome 30.5 SERPINE1 SERPINC1 F5
20 acute liver failure 30.5 F5 F2 ALB
21 varicose veins 30.5 VWF SERPINC1 MTHFR F5 F2
22 mastoiditis 30.4 MTHFR CRP
23 cardiac tamponade 30.4 NPPB F9 F2
24 thrombocytosis 30.4 SERPINC1 F3 F2 CRP
25 lemierre's syndrome 30.3 SERPINE1 MTHFR F3 CRP
26 thrombasthenia 30.3 MTHFR F5 F3 F2
27 amaurosis fugax 30.3 SERPINE1 MTHFR F5
28 portal hypertension 30.2 VWF F2 ALB
29 sagittal sinus thrombosis 30.2 SERPINC1 F5 F3 F2
30 constrictive pericarditis 30.2 NPPB ALB
31 vasculitis 30.2 VWF CRP APOH
32 peritonitis 30.2 F2 CRP ALB
33 factor viii deficiency 30.2 VWF F5 F2
34 intracranial embolism 30.2 SERPINF2 SERPINC1 PLAT F2
35 eclampsia 30.2 SERPINC1 MTHFR F2 ALB
36 thrombophilia due to thrombin defect 30.1 VWF SERPINE1 SERPINC1 PLAT MTHFR F5
37 arteriosclerosis 30.1 SERPINE1 F3 CRP
38 homocystinuria 30.1 SERPINC1 MTHFR F5
39 hypersplenism 30.1 SERPINC1 F2 ALB
40 mediastinitis 30.0 F5 CRP
41 infective endocarditis 30.0 TNNI3 SERPINE1 F2 CRP APOH
42 active peptic ulcer disease 30.0 VWF F2
43 cryptogenic cirrhosis 30.0 SERPINE1 MTHFR F5 F2
44 venous insufficiency 30.0 VWF SERPINE1 PLAT F2 CRP
45 acute pulmonary heart disease 30.0 SERPINF2 SERPINE1 PLAT NPPB
46 restrictive cardiomyopathy 29.9 TNNT2 TNNI3 NPPB
47 abdominal tuberculosis 29.9 F2 CRP ALB
48 coronary heart disease 1 29.9 SERPINE1 PLAT NPPB MTHFR CRP
49 homocysteinemia 29.9 SERPINC1 MTHFR F5 F2 CRP ALB
50 hepatic veno-occlusive disease 29.9 SERPINE1 SERPINC1 PLAT F3

Graphical network of the top 20 diseases related to Pulmonary Embolism:



Diseases related to Pulmonary Embolism

Symptoms & Phenotypes for Pulmonary Embolism

UMLS symptoms related to Pulmonary Embolism:


hemoptysis, snoring, coughing

MGI Mouse Phenotypes related to Pulmonary Embolism:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 CRP F10 F2 F3 F5 F9
2 homeostasis/metabolism MP:0005376 10.06 ALB APOH CRP F10 F2 F3
3 liver/biliary system MP:0005370 9.5 ALB F5 F9 FABP3 MTHFR SERPINC1
4 mortality/aging MP:0010768 9.5 ALB APOH F10 F2 F3 F5

Drugs & Therapeutics for Pulmonary Embolism

PubMed Health treatment related to Pulmonary Embolism: 63

Pulmonary embolism (PE) is treated with medicines, procedures, and other therapies. The main goals of treating PE are to stop the blood clot from getting bigger and keep new clots from forming. Treatment may include medicines to thin the blood and slow its ability to clot. If your symptoms are life threatening, your doctor may give you medicine to quickly dissolve the clot. Rarely, your doctor may use surgery or another procedure to remove the clot.

Drugs for Pulmonary Embolism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 393)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phenprocoumon Approved, Investigational Phase 4 435-97-2 9908 54680692
2
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
3
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
4
Dalteparin Approved Phase 4 9005-49-6
5
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
6
Phylloquinone Approved, Investigational Phase 4 84-80-0
7
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
8
Streptokinase Approved, Investigational Phase 4 9002-01-1
9
Epoprostenol Approved Phase 4 35121-78-9, 61849-14-7 5282411 5280427
10
Pancrelipase Approved, Investigational Phase 4 53608-75-6
11
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
12
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
13
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
14
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
15
Acetaminophen Approved Phase 4 103-90-2 1983
16 fluindione Approved, Investigational Phase 4 957-56-2
17
Ibuprofen Approved Phase 4 15687-27-1 3672
18
Dobutamine Approved Phase 4 34368-04-2 36811
19
Phenindione Approved, Investigational Phase 4 83-12-5 4760
20
Tinzaparin Approved Phase 4 9005-49-6, 9041-08-1 25244225
21
Nadroparin Approved, Investigational Phase 4
22
Edoxaban Approved Phase 4 480449-70-5
23
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
24
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
25
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
26
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
27
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
28
Betrixaban Approved, Investigational Phase 4 330942-05-7
29
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
31
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
32
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
33
Enoxaparin Approved Phase 4 9005-49-6 772
34
Iodine Approved, Investigational Phase 4 7553-56-2 807
35
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
36
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
37
Apixaban Approved Phase 4 503612-47-3 10182969
38
tannic acid Approved Phase 4 1401-55-4
39
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
40
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
41
Morphine Approved, Investigational Phase 4 57-27-2 5288826
42
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
43
Racepinephrine Approved Phase 4 329-65-7 838
44
Zinc Approved, Investigational Phase 4 7440-66-6 32051
45
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
46 Monteplase Investigational Phase 4 156616-23-8
47 Menaquinone Investigational Phase 4 1182-68-9
48 Tezosentan Investigational Phase 4 180384-57-0
49
Dabigatran Investigational Phase 4 211914-51-1
50
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7

Interventional clinical trials:

(show top 50) (show all 931)
# Name Status NCT ID Phase Drugs
1 Cooperative Investigation Plan for Home Treatment of Pulmonary Embolism Unknown status NCT00214929 Phase 4
2 A Safety and Efficacy Study for Implantation and Retrieval Procedures Using the VENATECH® Retrieval Filter System Unknown status NCT02674672 Phase 4
3 Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism: AYKAN Trial Unknown status NCT02029456 Phase 4 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours
4 A Prospective Randomised Controlled Study to Evaluate Outcomes of the Treatment With Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism Undergoing Endovascular Mechanical Fragmentation and Thrombolytic Therapy Unknown status NCT02979561 Phase 4 Dabigatran Etexilate;Warfarin
5 Low Dose Rt-PA Plus LMWH Compared With LMWH Alone for the Treatment of Normotensive Pulmonary Embolism Patients With Acute RV Dysfunction: A Randomized,Multi-Center,Controlled Trial Unknown status NCT01531829 Phase 4 Recombinant tissue plasminogen activator (rt-PA);Low Molecular Weight Heparin
6 Gadolinium Enhanced Dual-Energy Computed Tomography: A Feasibility Study to Assess Image Quality and Diagnostic Confidence Unknown status NCT02163005 Phase 4 Gadolinium
7 A Feasibility Study to Explore the Difference in Healing Time Between Teriparatide Treatment and Standard Care on Weber B Ankle Fractures in Older People Unknown status NCT02955056 Phase 4 Forsteo
8 Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis (TWISTER) Unknown status NCT01252420 Phase 4 Enoxaparin
9 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
10 Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis Unknown status NCT02959801 Phase 4
11 Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting Unknown status NCT00776633 Phase 4 aspirin;clopidogrel;oral anticoagulation
12 The Treatment Effect of Inhaled Corticosteroid and Long-acting beta2 Agonist Combination Versus Long-acting Anti-cholinergic Agent on Stratified COPD Patients Based on the Levels of Exhaled Nitric Oxide Unknown status NCT02546349 Phase 4 fluticasone/salmeterol, tiotropium
13 Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism Unknown status NCT01956955 Phase 4 enoxaparin ,alteplase, unfractionated heparin
14 Comparison of Combined Topical Tranexamic Acid With Floseal® With Intravenous Tranexamic Acid on Blood Loss in Total Knee Arthroplasty Unknown status NCT03328832 Phase 4 Topical tranexamic acid;Floseal®;rivaroxaban (10mg)
15 Effect of Intravenous Tranexamic Acid on Reduction of Blood Losses in Hip Fracture Patients. A Randomized, Controlled, Double-blind Study Unknown status NCT03211286 Phase 4 Tranexamic Acid;Saline Solution
16 Residual Vein Thrombosis Establishes the Optimal Duration of Low Molecular Weight Heparins in Cancer Patients With Deep Vein Thrombosis of the Lower Limbs Unknown status NCT00450645 Phase 4 low molecular weight heparin
17 The VICTORIA Study (Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation) Comparison Anti-vitamin K Versus Anti-Xa. Unknown status NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
18 Comparison of Topical Tranexamic Acid and Floseal® on Blood Loss After Total Knee Arthroplasty in Patients With a Thromboembolic Risk Unknown status NCT02865174 Phase 4 Topical tranexamic acid;Floseal®;Enoxaparin
19 Pharmacokinetic/Pharmacodynamic Study of Monteplase ("Cleactor") in Acute Pulmonary Embolism Completed NCT00442234 Phase 4 Monteplase
20 The Cordis Protection From Pulmonary Embolism With the Permanent OptEase™ Filter - A Post Marketing Surveillance Study (PROOF Study) Completed NCT00233740 Phase 4
21 Detection of Pulmonary Embolism Comparing Isovue-370 and Visipaque 320 Using 64-Slice Multi-Detector Computed Tomographic Angiography Completed NCT00351754 Phase 4 Isovue
22 Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism in Context of Pulmonary Hypertension, Right Heart Failure and Patient Functional Ability Completed NCT02132689 Phase 4 Actilyse (Thrombolytic therapy);Heparine (Standard anticoagulation therapy)
23 A Non-Randomized Prospective Study of IVC Filter Retrieval Completed NCT00196118 Phase 4
24 N-acetylcysteine, Sodium Bicarbonate and Normal Saline Alone Prophylaxis for Spiral Computed Tomography Pulmonary Angiography in the Emergency Department on Suspicion of Pulmonary Emboli: A Randomized Controlled Trial Completed NCT02483143 Phase 4 NAC;NaHCO3;Normal Saline
25 Long Term Subcutaneous Tinzaparin Compared With Tinzaparin and Oral Anticoagulants in the Treatment of the Acute Pulmonary Embolism Completed NCT00711308 Phase 4 tinzaparin;acenocoumarol
26 Clinical Trial of Two Durations of Warfarin Therapy in the Treatment of Deep Vein Thrombosis and/or Pulmonary Embolism Completed NCT00365950 Phase 4 Duration of anticoagulation;Warfarin duration
27 PREPIC 2 : Interruption of Inferior Vena Cava by a Retrievable Filter for the Prevention of Recurrent Pulmonary Embolism : a Randomised, Open Label Study Completed NCT00457158 Phase 4
28 MulticEnter Trial of Rivaroxaban for Early disCharge of pUlmonaRY Embolism From the Emergency Department Completed NCT02584660 Phase 4 Rivaroxaban;Standard-of-care
29 Effects of Intravenous Epoprostenol Sodium (Flolan®) in Patients With Moderate-to-Severe Pulmonary Thrombo-Embolism Completed NCT01014156 Phase 4 epoprostenol
30 Warfarin Dosing: Pharmacogenetic Algorithm Compared to Pharmacist's Dosing Completed NCT00511173 Phase 4
31 Age-adjusted D-dimer Cut-off Levels to Rule Out Pulmonary Embolism: a Prospective Outcome Study. Completed NCT01134068 Phase 4
32 Efficacy and Safety Evaluation of Recombinant Streptokinase and Urokinase in the Treatment of Pulmonary Embolism: A Multi-Center, Randomized Controlled Trial in China Completed NCT00968929 Phase 4 Recombinant Streptokinase;Urokinase
33 Chemoprophylaxis Plus Early Ambulation Prevent Chinese Thoracic Surgery Patients From Pulmonary Embolism Completed NCT03862755 Phase 4 Chemoprophylaxis with Low Molecular Weight Heparin (LMWH)
34 D-dimer Test to Establish Duration of Anticoagulation After a First Idiopathic Episode of Venous Thromboembolism; the Prospective Randomized "Prolong" Study Completed NCT00264277 Phase 4 Vitamin K antagonist (Coumarin anticoagulants)
35 Venous Thromboembolic Prophylaxis After Major Trauma: A Randomized Controlled Trial of Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin Completed NCT01729559 Phase 4 5000 Units unfractionated Heparin Q 8 hr;30mg enoxaparin Q12 hr
36 Objective Assessment of Pulmonary Embolism Can be Deferred Without Increased Risk Completed NCT00381511 Phase 4 low molecular weight heparin
37 Prospective Randomized Trial of a Clinical Algorithm to Predict the Loading Dose of Phenprocoumon Completed NCT00586287 Phase 4 Phenprocoumon
38 Does Anticoagulant Control Change Following Referral Back to the Primary Care Physician? A Prospective Randomized Trial Completed NCT00735189 Phase 4
39 Prospective, Multicenter Study Investigating Efficacy and Safety of Oral Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism in Korean Patients With Cancers Completed NCT01989845 Phase 4 Rivaroxaban
40 Efficacy of Tranexamic Acid in Reducing Perioperative Bleeding in Patients Undergoing Radical Prostatectomy. A Randomized Controlled Double-blind Study. Completed NCT00670345 Phase 4 Tranexamic Acid;Placebo
41 Mepivacaine vs. Bupivacaine Spinal Anesthetic in Total Knee Arthroplasty, a Randomized Controlled Clinical Trial Completed NCT02980926 Phase 4 Mepivacaine;Bupivacaine
42 Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid Completed NCT00603317 Phase 4 Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo;Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid
43 Efficacy and Safety Evaluation of Low Dosage of Recombinant Tissue Plasminogen Activator (rt-PA) in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China Completed NCT00781378 Phase 4 rt-PA;rt-PA
44 Cystic Fibrosis and Totally Implantable Vascular Access Devices: Evaluation of the Incidence of Venous Thrombosis Related to the Catheter and Study of the Genetic and Acquired Risk Factors Completed NCT00244270 Phase 4
45 Efficacy and Safety Evaluation of 12-h and 2-h Urokinase Regimes in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China Completed NCT00799968 Phase 4 Urokinase;Urokinase
46 Efficacy and Safety of Body Weight Adjusted Nadroparin vs Standard Unfractionated Heparin for the Initial Treatment of Pulmonary Thromboembolism:a Multi-Centre, Randomised Controlled Trial in China Completed NCT00796692 Phase 4 Nadroparin;Unfractionated heparin(UFH)
47 Use of Fondaparinux in Critically Ill Patients With Renal Failure Completed NCT01467583 Phase 4 Fondaparinux
48 Treatment of Upper Extremity Deep-Vein Thrombosis Completed NCT00245856 Phase 4 Dalteparin sodium injection;Warfarin
49 Dose-dependent Drug-drug Interaction Between Paracetamol and Warfarin in Adults Receiving Long-term Oral Anticoagulants: A Randomized Controlled Trial Completed NCT01104337 Phase 4 paracetamol;paracetamol;Placebo
50 Diagnostic Value of Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Undifferentiated Acute Chest Pain Completed NCT01067456 Phase 4

Search NIH Clinical Center for Pulmonary Embolism

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acenocoumarol
alteplase
Alteplase
anisindione
Anistreplase
apixaban
Apixaban
Dabigatran etexilate
Dalteparin
Dalteparin Sodium
danaparoid
Danaparoid sodium
Dextran
Dicumarol
Dihydroergotamine
Edoxaban
Enoxaparin
heparin
Heparin
heparin calcium
heparin sodium
HEPARIN SODIUM (BEEF LUNG)
heparin sodium, bovine
heparin sodium, porcine
Nadroparin
Papaverine
Papaverine Hydrochloride
Phenprocoumon
rivaroxaban
Rivaroxaban
Streptokinase
tinzaparin
Tinzaparin sodium
Urokinase
Warfarin
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Cochrane evidence based reviews: pulmonary embolism

Genetic Tests for Pulmonary Embolism

Genetic tests related to Pulmonary Embolism:

# Genetic test Affiliating Genes
1 Pulmonary Embolism 29

Anatomical Context for Pulmonary Embolism

MalaCards organs/tissues related to Pulmonary Embolism:

41
Lung, Heart, Testes, Liver, Brain, Breast, Bone

Publications for Pulmonary Embolism

Articles related to Pulmonary Embolism:

(show top 50) (show all 31793)
# Title Authors PMID Year
1
Imaging of Cardiovascular Thoracic Emergencies: Acute Aortic Syndrome and Pulmonary Embolism. 38 17
31076032 2019
2
A Multicenter Trial of Vena Cava Filters in Severely Injured Patients. 38 17
31259488 2019
3
State of the art: utility of multi-energy CT in the evaluation of pulmonary vasculature. 17
31049753 2019
4
Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study. 9 38
20007142 2010
5
Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox. 9 38
20513806 2010
6
Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. 9 38
20447541 2010
7
Etanercept and venous thromboembolism: a case series. 9 38
20157435 2010
8
Clinical usefulness of prothrombin fragment 1+2 in patients with suspected pulmonary embolism. 9 38
19394681 2010
9
A serious drug interaction leading to spontaneous total hyphema. 9 38
20393256 2010
10
[High-risk factors and clinical pathological analysis in 21 cases of fatal pulmonary embolism]. 9 38
20019774 2009
11
Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis. 9 38
19525265 2009
12
Concurrent administration of heparin and activated protein C in a patient with pulmonary embolism and severe sepsis with positive outcome. 9 38
20040816 2009
13
Thrombophilia-related genetic variations in patients with pulmonary embolism in the main teaching hospital in Jordan. 9 38
19618008 2009
14
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. 9 38
19247590 2009
15
Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study. 9 38
19087222 2009
16
N-terminal pro-B-type natriuretic peptide predicts the burden of pulmonary embolism. 9 38
19214022 2009
17
Thrombo-embolic occlusion of the left anterior descending coronary artery complicating left atrial radiofrequency ablation. 9 38
18988653 2009
18
[Heparin-induced thrombocythopenia in a patient with massive pulmonary embolism and dilated cardiomyopathy, successfuly treated with fondaparinux - a case report]. 9 38
19169978 2008
19
Natriuretic peptides in acute pulmonary embolism: a systematic review. 9 38
18626627 2008
20
B-type natriuretic peptide in acute pulmonary embolism. 9 38
18706401 2008
21
[Massive pulmonary embolism]. 9 38
18775637 2008
22
[Oral contraceptives use increases venous thromboembolic risk even for minor surgical procedure - a case report]. 9 38
19006032 2008
23
Mechanisms of the factor V Leiden paradox. 9 38
18617648 2008
24
Effectiveness and cost effectiveness of thrombolysis in patients with acute pulmonary embolism. 9 38
18664972 2008
25
Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. 9 38
18556626 2008
26
Comparison of 8 biomarkers for prediction of right ventricular hypokinesis 6 months after submassive pulmonary embolism. 9 38
18657661 2008
27
[Massive pulmonary embolism treated with a reduced dose of alteplase in a patient with acute renal failure]. 9 38
18803142 2008
28
B-type natriuretic peptide as an indicator of right ventricular dysfunction in acute pulmonary embolism. 9 38
17537186 2008
29
Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. 9 38
18495689 2008
30
Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension. 9 38
18256058 2008
31
Mycoplasma pneumonia and pulmonary embolism in a child due to acquired prothrombotic factors. 9 38
18041082 2008
32
Epidural hematoma following tissue plasminogen activator (tPA) therapy for pulmonary embolism in a pediatric patient with stage IV Burkitt's lymphoma: a case report. 9 38
17854866 2008
33
Recurrent thrombembolic risk in patients with multiple thrombophilic disorders. 9 38
19366087 2008
34
Prognostic value of brain natriuretic peptide in acute pulmonary embolism. 9 38
18721456 2008
35
[The efficacy of alteplase in pulmonary embolism treatment]. 9 38
18833155 2008
36
Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure. 9 38
18158473 2008
37
Correlation between cardiac biomarkers and right ventricular enlargement on chest CT in non massive pulmonary embolism. 9 38
17716710 2008
38
HyBeacon probes for rapid DNA sequence detection and allele discrimination. 9 38
18695966 2008
39
Persistent NT-proBNP elevation in acute pulmonary embolism predicts early death. 9 38
17507005 2007
40
Paradoxical embolus illustrating speed of action of recombinant tissue plasminogen activator in massive pulmonary embolism. 9 38
17513552 2007
41
Tenecteplase to treat pulmonary embolism in the emergency department. 9 38
17221330 2007
42
Combined utility of brain natriuretic peptide and cardiac troponin T may improve rapid triage and risk stratification in normotensive patients with pulmonary embolism. 9 38
16814410 2007
43
Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. 9 38
17345160 2007
44
Spotlight on reteplase in thrombotic occlusive disorders. 9 38
17263591 2007
45
Heart-type fatty acid-binding proteins (H-FABP): a reliable tool for initial risk stratification of pulmonary embolism? 9 38
17208938 2007
46
[Value of plasma BNP levels as a prognostic marker in lung and heart disorders]. 9 38
17978918 2007
47
Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: a controlled study of 5,000 patients. 9 38
17145624 2007
48
Massive pulmonary embolism secondary to anticardiolipin antibody syndrome. 9 38
17256569 2007
49
Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. 9 38
17127709 2007
50
Evaluation of B-type natriuretic peptide to predict complicated pulmonary embolism in patients aged 65 years and older: brief report. 9 38
16938601 2006

Variations for Pulmonary Embolism

Expression for Pulmonary Embolism

Search GEO for disease gene expression data for Pulmonary Embolism.

Pathways for Pulmonary Embolism

Pathways related to Pulmonary Embolism according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.01 VWF SERPINF2 SERPINE1 SERPINC1 PLAT F9
2
Show member pathways
12.61 SERPINC1 F9 F5 F3 F2 F10
3
Show member pathways
12.07 SERPINE1 PLAT MTHFR F2 CRP ALB
4
Show member pathways
11.86 VWF SERPINF2 SERPINE1 SERPINC1 PLAT F9
5
Show member pathways
11.64 F9 F2 F10
6 11.47 VWF SERPINF2 SERPINE1 SERPINC1 PLAT F9
7 10.72 F9 F2 F10
8 10.61 SERPINF2 SERPINE1 PLAT

GO Terms for Pulmonary Embolism

Cellular components related to Pulmonary Embolism according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.8 SERPINC1 F9 F5 F2 F10 ALB
2 extracellular region GO:0005576 9.8 VWF SERPINF2 SERPINE1 SERPINC1 PLAT NPPB
3 blood microparticle GO:0072562 9.73 SERPINF2 SERPINC1 F2 ALB
4 collagen-containing extracellular matrix GO:0062023 9.7 VWF SERPINF2 SERPINE1 SERPINC1 PLAT F3
5 Golgi lumen GO:0005796 9.69 F9 F2 F10
6 platelet alpha granule lumen GO:0031093 9.65 VWF SERPINF2 SERPINE1 F5 ALB
7 platelet alpha granule GO:0031091 9.52 VWF F5
8 troponin complex GO:0005861 9.49 TNNT2 TNNI3
9 cardiac myofibril GO:0097512 9.48 TNNT2 TNNI3
10 extracellular space GO:0005615 9.47 SERPINF2 SERPINE1 SERPINC1 PLAT NPPB FABP3
11 intrinsic component of external side of plasma membrane GO:0031233 9.46 F3 F10
12 cardiac Troponin complex GO:1990584 9.4 TNNT2 TNNI3
13 extracellular exosome GO:0070062 10.07 VWF SERPINF2 SERPINE1 SERPINC1 PLAT FABP3

Biological processes related to Pulmonary Embolism according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.83 SERPINC1 F5 F2 ALB
2 ER to Golgi vesicle-mediated transport GO:0006888 9.81 F9 F5 F2 F10
3 negative regulation of peptidase activity GO:0010466 9.74 SERPINF2 SERPINE1 SERPINC1
4 platelet degranulation GO:0002576 9.73 VWF SERPINF2 SERPINE1 F5 APOH ALB
5 fibrinolysis GO:0042730 9.67 SERPINF2 SERPINE1 PLAT F2
6 acute-phase response GO:0006953 9.63 SERPINF2 F2 CRP
7 blood coagulation, intrinsic pathway GO:0007597 9.62 VWF F9 F2 APOH
8 regulation of blood coagulation GO:0030193 9.61 SERPINC1 F2 APOH
9 regulation of muscle contraction GO:0006937 9.58 TNNT2 TNNI3
10 positive regulation of blood coagulation GO:0030194 9.58 SERPINE1 F2 APOH
11 negative regulation of blood coagulation GO:0030195 9.56 SERPINE1 APOH
12 blood coagulation GO:0007596 9.56 VWF SERPINC1 PLAT F9 F5 F3
13 negative regulation of ATPase activity GO:0032780 9.55 TNNT2 TNNI3
14 plasminogen activation GO:0031639 9.54 PLAT APOH
15 negative regulation of plasminogen activation GO:0010757 9.49 SERPINF2 SERPINE1
16 blood coagulation, extrinsic pathway GO:0007598 9.48 F3 F10
17 negative regulation of fibrinolysis GO:0051918 9.46 SERPINF2 SERPINE1 F2 APOH
18 hemostasis GO:0007599 9.17 VWF SERPINC1 F9 F5 F3 F2

Molecular functions related to Pulmonary Embolism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 VWF TNNT2 TNNI3 SERPINF2 SERPINE1 SERPINC1
2 serine-type peptidase activity GO:0008236 9.62 PLAT F9 F2 F10
3 peptidase inhibitor activity GO:0030414 9.61 SERPINF2 SERPINE1 SERPINC1
4 phospholipid binding GO:0005543 9.58 F3 F10 APOH
5 serine-type endopeptidase activity GO:0004252 9.55 PLAT F9 F3 F2 F10
6 serine-type endopeptidase inhibitor activity GO:0004867 9.54 SERPINF2 SERPINE1 SERPINC1
7 troponin C binding GO:0030172 9.26 TNNT2 TNNI3
8 protease binding GO:0002020 9.02 VWF SERPINF2 SERPINE1 SERPINC1 F3

Sources for Pulmonary Embolism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....